2nd Department of Cardiology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Am J Cardiol. 2021 Feb 1;140:25-32. doi: 10.1016/j.amjcard.2020.10.051. Epub 2020 Nov 2.
Type 2 diabetes mellitus (DM) has a detrimental impact on cardiovascular outcomes, with implications for prognosis following ST elevation myocardial infarction (STEMI).The aim was to evaluate the impact of DM and myocardial perfusion on the long-term risk of heart failure (HF) and/or all-cause mortality following primary percutaneous coronary intervention (pPCI) for STEMI. A total of 406 STEMI patients (104 with DM) treated with pPCI were enrolled in this observational study. Myocardial perfusion was reassessed with the Quantitative Myocardial Blush Evaluator. Follow-up data on HF (ICD10 [International Statistical Classification of Diseases] codes I50.0 - I50.9) and all-cause mortality were obtained from the National Health Fund. During a 6-year follow-up, 36 (35%) patients with DM died compared with 45 (15%) patients without DM (p <0.001). Also, 24 (23%) patients with DM developed HF compared with 51 (17%) patients without DM (p = 0.20). Patients with DM and HF had the highest mortality rate (75%), and those with DM and a QuBE score below the median value (9.0 arb. units) had significantly higher risk of HF (hazard ratio [HR] =1.96, 95% CI 1.18 to 3.27, p = 0.0099) and the composite of HF and/or all-cause mortality (HR = 1.89, 95% CI 1.33 to 2.69, p = 0.0004). In conclusion DM (type 2) and diminished myocardial perfusion increase the risk of HF and/or all-cause mortality during a 6-year follow-up after pPCI for STEMI.
2 型糖尿病(DM)对心血管结局有不利影响,对 ST 段抬高型心肌梗死(STEMI)后的预后有影响。目的是评估 DM 和心肌灌注对 STEMI 患者行直接经皮冠状动脉介入治疗(pPCI)后心力衰竭(HF)和/或全因死亡率的长期风险的影响。这项观察性研究共纳入 406 例接受 pPCI 治疗的 STEMI 患者(104 例合并 DM)。使用定量心肌灌注评估器重新评估心肌灌注。从国家健康基金获得 HF(ICD10 [国际疾病分类]代码 I50.0 - I50.9)和全因死亡率的随访数据。在 6 年的随访中,36 例(35%)DM 患者死亡,而 45 例(15%)非 DM 患者死亡(p <0.001)。此外,24 例(23%)DM 患者发生 HF,而 51 例(17%)非 DM 患者发生 HF(p = 0.20)。DM 合并 HF 的患者死亡率最高(75%),DM 合并 QuBE 评分低于中位数(9.0 arb. units)的患者发生 HF 的风险显著增加(危险比 [HR] =1.96,95%CI 1.18 至 3.27,p = 0.0099)和 HF 和/或全因死亡率的复合终点(HR =1.89,95%CI 1.33 至 2.69,p = 0.0004)。总之,DM(2 型)和心肌灌注减少增加了 STEMI 患者 pPCI 后 6 年随访期间 HF 和/或全因死亡率的风险。